Phoenix Molecular Designs Ltd.: federal grants and contributions: 6 agreements; $1.3M value; 1 departments; 3 programs.
Assay record ASY-CA-15HOVYO0D7 · Cite as: Assay Systems, “Phoenix Molecular Designs Ltd.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/phoenix-molecular-designs-ltd/
Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common receptor targets for current breast cancer chemotherapies. TNBC represents 15-25% of all breast cancers, and RSK represents a novel target for TNBC. PMD-026 is a first-in-class RSK inhibitor, and the proposed Project will assess pre-clinical safety of this lead compound in relevant animal models and investigate potential drug-drug interactions, in anticipation of IND submission and human trials.
The Firm has identified a lead compound with novel target to be developed into a potential therapeutic for triple-negative breast cancers (TNBC). This project seeks to develop an advanced formulation for delivery, evaluate the performance of the lead in combination therapies and evaluate the ability of the lead compound to overcome resistance in in vitro models (in anticipation of future in vivo studies).
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.